97 related articles for article (PubMed ID: 10909192)
1. Bioanalysis of syn dimeric HIV-1 protease inhibitor N-benzyl 4-aryl-1,4-dihydropyridine H19: metabolic and cytotoxic properties in Hep G2 cells.
Hilgeroth A; Langner A
Arch Pharm (Weinheim); 2000 Jun; 333(6):195-7. PubMed ID: 10909192
[TBL] [Abstract][Full Text] [Related]
2. First bioanalytical evaluation of nonpeptidic cage dimeric HIV-1 protease inhibitor N-benzyl 4-aryl-1,4-dihydropyridine H17: biotransformation and toxicity on Hep G2 cells.
Hilgeroth A; Langner A
Arch Pharm (Weinheim); 2000 Jan; 333(1):32-4. PubMed ID: 10675987
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of first N-alkyl syn dimeric 4-aryl-1,4-dihydropyridines as competitive HIV-1 protease inhibitors.
Hilgeroth A; Billich A; Lilie H
Eur J Med Chem; 2001 Apr; 36(4):367-74. PubMed ID: 11461762
[TBL] [Abstract][Full Text] [Related]
4. A symmetric inhibitor binds HIV-1 protease asymmetrically.
Dreyer GB; Boehm JC; Chenera B; DesJarlais RL; Hassell AM; Meek TD; Tomaszek TA; Lewis M
Biochemistry; 1993 Jan; 32(3):937-47. PubMed ID: 8422397
[TBL] [Abstract][Full Text] [Related]
5. Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cage dimeric N-benzyl 4-(4-methoxyphenyl)-1,4-dihydropyridine as representative of a novel class of HIV-1 protease inhibitors: a molecular modeling study.
Hilgeroth A; Fleischer R; Wiese M; Heinemann FW
J Comput Aided Mol Des; 1999 May; 13(3):233-42. PubMed ID: 10216831
[TBL] [Abstract][Full Text] [Related]
6. Dimeric 4-Aryl-1,4-dihydropyridines: development of a third class of nonpeptidic HIV-1 protease inhibitors.
Hilgeroth A
Mini Rev Med Chem; 2002 Jun; 2(3):235-45. PubMed ID: 12370065
[TBL] [Abstract][Full Text] [Related]
7. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
[TBL] [Abstract][Full Text] [Related]
8. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of the first N-alkyl cage dimeric 4-aryl-1,4-dihydropyridines as novel nonpeptidic HIV-1 protease inhibitors.
Hilgeroth A; Wiese M; Billich A
J Med Chem; 1999 Nov; 42(22):4729-32. PubMed ID: 10579836
[TBL] [Abstract][Full Text] [Related]
10. Cage dimeric N-acyl- and N-acyloxy-4-aryl-1,4-dihydropyridines as first representatives of a novel class of HIV-1 protease inhibitors.
Hilgeroth A; Billich A
Arch Pharm (Weinheim); 1999 Nov; 332(11):380-4. PubMed ID: 10605378
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
Ghosh AK; Sridhar PR; Leshchenko S; Hussain AK; Li J; Kovalevsky AY; Walters DE; Wedekind JE; Grum-Tokars V; Das D; Koh Y; Maeda K; Gatanaga H; Weber IT; Mitsuya H
J Med Chem; 2006 Aug; 49(17):5252-61. PubMed ID: 16913714
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of pseudo-symmetric HIV protease inhibitors containing a novel hydroxymethylcarbonyl (HMC)-hydrazide isostere.
Hidaka K; Kimura T; Hayashi Y; McDaniel KF; Dekhtyar T; Colletti L; Kiso Y
Bioorg Med Chem Lett; 2003 Jan; 13(1):93-6. PubMed ID: 12467624
[TBL] [Abstract][Full Text] [Related]
13. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
Miller JF; Furfine ES; Hanlon MH; Hazen RJ; Ray JA; Robinson L; Samano V; Spaltenstein A
Bioorg Med Chem Lett; 2004 Feb; 14(4):959-63. PubMed ID: 15013001
[TBL] [Abstract][Full Text] [Related]
14. Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.
Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Hagen SE; Markoski LJ; Steinbaugh BA; Tait BD; Humblet C; Lunney EA; Pavlovsky A; Rubin JR; Ferguson D; Graham N; Holler T; Hupe D; Nouhan C; Tummino PJ; Urumov A; Zeikus E; Zeikus G; Gracheck SJ; Erickson JW
Bioorg Med Chem; 1999 Dec; 7(12):2775-800. PubMed ID: 10658583
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease.
Mo H; Markowitz M; Majer P; Burt SK; Gulnik SV; Suvorov LI; Erickson JW; Ho DD
AIDS Res Hum Retroviruses; 1996 Jan; 12(1):55-61. PubMed ID: 8825619
[TBL] [Abstract][Full Text] [Related]
16. Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.
Cheng Y; Zhang F; Rano TA; Lu Z; Schleif WA; Gabryelski L; Olsen DB; Stahlhut M; Rutkowski CA; Lin JH; Jin L; Emini EA; Chapman KT; Tata JR
Bioorg Med Chem Lett; 2002 Sep; 12(17):2419-22. PubMed ID: 12161147
[TBL] [Abstract][Full Text] [Related]
17. Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones.
Janakiraman MN; Watenpaugh KD; Tomich PK; Chong KT; Turner SR; Tommasi RA; Thaisrivongs S; Strohbach JW
Bioorg Med Chem Lett; 1998 May; 8(10):1237-42. PubMed ID: 9871742
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates.
Song M; Rajesh S; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2001 Sep; 11(18):2465-8. PubMed ID: 11549448
[TBL] [Abstract][Full Text] [Related]
19. Novel nonpeptidic inhibitors of HIV-1 protease obtained via a new multicomponent chemistry strategy.
Yehia NA; Antuch W; Beck B; Hess S; Schauer-Vukasinović V; Almstetter M; Furer P; Herdtweck E; Dömling A
Bioorg Med Chem Lett; 2004 Jun; 14(12):3121-5. PubMed ID: 15149657
[TBL] [Abstract][Full Text] [Related]
20. A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
Amano M; Salcedo-Gómez PM; Zhao R; Yedidi RS; Das D; Bulut H; Delino NS; Sheri VR; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7046-7059. PubMed ID: 27620483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
